Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice
Allergy · 2025
DOI: 10.1111/all.16485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Evelien Maria Hutten und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Allergology, University Medical Center Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: beta-Lactams, Anti-Bacterial Agents, Drug Hypersensitivity. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In patients with a beta‐lactam antibiotic (BA) allergy label, avoidance of the whole group of BAs leads to displacement of first‐line therapies potentially influencing patient outcomes and antimicrobial resistance. Studies previously published on BA cross‐reactivity use different sets of BA and seem to contain conflicting recommendations on safe BA alternatives in case of (suspected) BA allergy.
Methods
The objectives were (i) to identify discrepancies between studies regarding cross‐allergy in BA and (ii) to identify research gaps. The tables and errata of 4 studies (Romano et al., Trubiano et al., Zagursky et al., SWAB‐guideline by Wijnakker et al.) were evaluated and compared head‐to‐head.
Results
A total of 51 antibiotics were covered by the four authors, theoretically leading to 2550 potential recommendations regarding alternatives in case of specific allergies. Internal discrepancies existed in 2 tables. Since none of the tables included all 51 BAs, in 356 situations data were lacking regarding specific alternatives. In 1104 situations, only one author gave advice about a specific alternative. Harmony and disharmony between authors could be evaluated in 1090 cases. The advice regarding alternative BAs was 696 times in harmony (482 safe, 214 unsafe), while discrepancies were found in 394 cases. This led to a different advice (safe vs. unsafe) in 272 cases or 69%.
Conclusion
Disharmony between authors was identified in 36% of the cases. In 69%, this led to a clinically relevant, different advice. This indicates the need for synchronisation of cross‐reactivity tables and answering remaining research gaps.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Allergology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Laboratory Specialised Diagnostics & Research, Department of Laboratory Medicine, Amsterdam, the Netherlands.
- Centre for Antibiotic Allergy and Research, Department of Infectious Diseases and Immunology, Heidelberg, Victoria, Australia.
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
- ENT Department, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
ORCID-Profile: Evelien Maria Hutten, Maja Bulatović Ćalasan, Jason Anthony Trubiano, Rick Gert-Jan Pleijhuis, Ingrid Terreehorst
Zitieren
APA
Hutten, E. M., Bulatović Ćalasan, M., Trubiano, J. A., Pleijhuis, R. G., & Terreehorst, I. (2025). Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice. Allergy. https://doi.org/10.1111/all.16485
Vancouver
Hutten EM, Bulatović Ćalasan M, Trubiano JA, Pleijhuis RG, Terreehorst I. Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice. Allergy. 2025. doi:10.1111/all.16485
BibTeX
@article{Hutten2025,
author = {Hutten, Evelien Maria and Bulatović Ćalasan, Maja and Trubiano, Jason Anthony and Pleijhuis, Rick Gert-Jan and Terreehorst, Ingrid},
title = {Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16485}
}
EUVIMED